Summary by Futu AI
New Ray Medic International Holdings Limited announced its interim performance for the six months ended June 30, 2024, showing a decrease in profit of 46.1% compared to the same period last year, to approximately HKD 0.167 billion. The net loss attributable to owners of the company decreased by 69.4%, to approximately HKD 4.088 million. No interim dividends were distributed during this period. The company attributed the decrease in profit mainly to the enhanced tiered classification and management policy for antibacterial drugs in mainland China, which resulted in a decrease in demand for the main products. In addition, the company engaged in various investment activities during the period, including acquiring equity interests in target companies and participating in cornerstone investments. The company also mentioned that there were no significant lawsuits, arbitrations, or claims during the period, and that it had complied with corporate governance guidelines. Ms. Wang Qiuqin, Chairperson, CEO, and Executive Director of the Board, stated that the company will continue to review its structure and search for a suitable candidate to serve as Chairperson.